Dokmanovic Lidija, Krstovski Nada, Vukanic Dragan, Brasanac Dimitrije, Rodic Predrag, Cvetkovic Mirjana, Janic Dragana
Department of Hematology/Oncology, University Children's Hospital, School of Medicine, University of Belgrade, Belgrade, Serbia.
Pediatr Hematol Oncol. 2012 Mar;29(2):109-18. doi: 10.3109/08880018.2011.652342.
Use of current intensive chemotherapy protocols in pediatric non-Hodgkin lymphoma (NHL) in high-income countries resulted in event-free survival (EFS) rates ranging from 80 to 90%. The results are inferior in less privileged countries with limited resources for medical care. There are no reports about comprehensive data analysis in pediatric NHL in Serbia. A retrospective study was carried out at University Children's Hospital, Belgrade, in children aged less than 18 years diagnosed with non-Hodgkin lymphoma from 1997 to 2011. Fifty-seven children were eligible for analysis. Fourteen were diagnosed with lymphoblastic lymphoma, 38 with mature B-cell NHL (B-NHL), and 5 with anaplastic large-cell lymphoma. Mean age at diagnosis was 9.2 years, with male to female ratio 2.35:1. Children were treated according to Berlin-Frankfurt-Münster (BFM) protocols. With median follow-up of 59.3 months, 5-year probability of EFS was 84.1% for all patients, whereas overall survival was 93%. These results with BFM protocol administration, although inferior to leading international groups, reflect good treatment outcome in our patients. To the best of the authors' knowledge, this article presents the first results regarding treatment and survival of childhood NHL in Serbia.
在高收入国家，目前用于治疗儿童非霍奇金淋巴瘤（NHL）的强化化疗方案可使无事件生存率（EFS）达到80%至90%。而在医疗资源有限的较贫困国家，治疗结果则较差。塞尔维亚尚无关于儿童NHL综合数据分析的报告。贝尔格莱德大学儿童医院对1997年至2〇11年期间诊断为非霍奇金淋巴瘤的18岁以下儿童进行了一项回顾性研究。57名儿童符合分析条件。其中14名被诊断为淋巴细胞白血病，38名被诊断为成熟B细胞NHL（B-NHL），5名被诊断为间变性大细胞淋巴瘤。诊断时的平均年龄为9.2岁，男女比例为2.35:1。患儿按照柏林-法兰克福-明斯特（BFM）方案进行治疗。中位随访时间为59.3个月，所有患者的5年EFS概率为84.1%，总生存率为93%。尽管采用BFM方案治疗的结果不如国际领先团队，但反映出我们的患者治疗效果良好。据作者所知，本文首次介绍了塞尔维亚儿童NHL的治疗和生存结果。
